N legislation on the use of animals for research (DLgs. 116/92) and with NIH guidelines for animal care.To generate the relaxin expression constructs, RLN1-V5/ His,RLN1-Ea-V5/His, RLN1-Eb-V5/His, cDNA of mouse relaxin was cloned into pcDNA3.1-V5/His vector (Invitrogen), Epeptides were added using the QuikChange method (Stratagene).Cell Cultures and Transfection Generation and Characterization of IGF-1 Transgenic Mouse LinesSP1-IGF-1Ea ( = MLC/mIGF-1) transgenic line has been described previously [11]. Skeletal muscle specific SP1-IGF-1Eb, SP2-IGF-1Ea and SP2-IGF-1Eb expression constructs were generated by cloning the respective mouse cDNA sequences into the skeletal muscle-specific expression cassette containing the myosin light chain (MLC) 1/3 promoter and the SV40 polyadenylation signal, followed by the MLC 1/3 enhancer sequence [39] [11,40] (See Sup. Figure 1B). IGF-1 cDNAs were cloned by RT-PCR from mouse liver using the primers listed in Table 2. Transgenic animals were generated by pronuclear HIV-RT inhibitor 1 site injection using FVB mice as embryo donors. Positive founders were bred to FVB wild-type mice and positive transgenic mice were selected by PCR from tail digests (for primer sequence see Table 2). Primers were designed to recognize all IGF-1 isoforms by choosing a forward primer located in exon 4 and a reverse primer located in the SV40 polyadenylation signal sequence. Transgenic founders were analyzed for skeletal muscle-specific expression (Figure S2A) and were selected for high but AVP site comparable transgene expression levels. One founder for each line was selected and phenotype analysis was carried out on male animals. All data was compared to the previously well-described 18297096 MLC/mIGF-1 ( = SP1-IGF-1Ea) transgenic line [11]. Comparison of IGF-1 expression levels was performed by Northern Blot (Sup. Figure 2B) and by western blot (Figure S2D) analysis. HEK 293 cells were cultured in growth medium (DMEM supplemented with 10 fetal bovine serum (FBS), 2 mM Lglutamine, 1 mM Na-pyrovate, 10 mM HEPES and 16 NEAA (all from Gibco/Invitrogen). Transient transfections were performed with LipofectamineTM 2000 (Invitrogen) according to the manufacturer’s instructions. Medium was harvested 24?0 hours after transfection.Immunoenzymometric Assay (IEMA)To determine circulating IGF-1 levels and IGF-1 levels in the conditioned growth media, OCTEIA Rat/Mouse IGF-1 IEMA (iDS) was used according to the manufacturer’s instructions.Binding to Tissue Culture Surfaces and Heparin AgaroseBD PureCoat plates (Carboxyl ?negatively charged and Amine ?positively charge), and immobilized heparine (Thermo Scientific, 20207) and control agarose beads (Thermo Scientific, 26150) were used for in vitro binding experiments. 500 uL of conditioned growth medium (with IGF-1 levels normalized to 200 ng/mL) was incubated in the wells of the tissue culture plates or with agarose beads for 1 hour at 37C. The plates or agarose beads were then washed 3 times with PBS and the bound proteins extracted with 50 ml 16 SDS loading buffer.ImmunoblottingProtein extracts from mouse tissues were prepared in RIPA lysis buffer (20 mM Tris pH 8.0, 5 mM MgCl2, 150 mM NaCl, 1 NP40, 0.1 Triton X, 1 mM NaVO4, 1 mM NaF, 1 mM PMSF, 1 ug/ml of Aprotinin and Leopeptin). 30?0 ug of protein lysates were used for 24272870 each sample, separated by SDS-page, and immunoblotted. Filters were blocked in 5 milk (Roth, T145.1) in TBST (20 mM Tris pH 7.5, 140 mM NaCl, 0.1 Tween20). Primary and secondary antibodies were diluted in.N legislation on the use of animals for research (DLgs. 116/92) and with NIH guidelines for animal care.To generate the relaxin expression constructs, RLN1-V5/ His,RLN1-Ea-V5/His, RLN1-Eb-V5/His, cDNA of mouse relaxin was cloned into pcDNA3.1-V5/His vector (Invitrogen), Epeptides were added using the QuikChange method (Stratagene).Cell Cultures and Transfection Generation and Characterization of IGF-1 Transgenic Mouse LinesSP1-IGF-1Ea ( = MLC/mIGF-1) transgenic line has been described previously [11]. Skeletal muscle specific SP1-IGF-1Eb, SP2-IGF-1Ea and SP2-IGF-1Eb expression constructs were generated by cloning the respective mouse cDNA sequences into the skeletal muscle-specific expression cassette containing the myosin light chain (MLC) 1/3 promoter and the SV40 polyadenylation signal, followed by the MLC 1/3 enhancer sequence [39] [11,40] (See Sup. Figure 1B). IGF-1 cDNAs were cloned by RT-PCR from mouse liver using the primers listed in Table 2. Transgenic animals were generated by pronuclear injection using FVB mice as embryo donors. Positive founders were bred to FVB wild-type mice and positive transgenic mice were selected by PCR from tail digests (for primer sequence see Table 2). Primers were designed to recognize all IGF-1 isoforms by choosing a forward primer located in exon 4 and a reverse primer located in the SV40 polyadenylation signal sequence. Transgenic founders were analyzed for skeletal muscle-specific expression (Figure S2A) and were selected for high but comparable transgene expression levels. One founder for each line was selected and phenotype analysis was carried out on male animals. All data was compared to the previously well-described 18297096 MLC/mIGF-1 ( = SP1-IGF-1Ea) transgenic line [11]. Comparison of IGF-1 expression levels was performed by Northern Blot (Sup. Figure 2B) and by western blot (Figure S2D) analysis. HEK 293 cells were cultured in growth medium (DMEM supplemented with 10 fetal bovine serum (FBS), 2 mM Lglutamine, 1 mM Na-pyrovate, 10 mM HEPES and 16 NEAA (all from Gibco/Invitrogen). Transient transfections were performed with LipofectamineTM 2000 (Invitrogen) according to the manufacturer’s instructions. Medium was harvested 24?0 hours after transfection.Immunoenzymometric Assay (IEMA)To determine circulating IGF-1 levels and IGF-1 levels in the conditioned growth media, OCTEIA Rat/Mouse IGF-1 IEMA (iDS) was used according to the manufacturer’s instructions.Binding to Tissue Culture Surfaces and Heparin AgaroseBD PureCoat plates (Carboxyl ?negatively charged and Amine ?positively charge), and immobilized heparine (Thermo Scientific, 20207) and control agarose beads (Thermo Scientific, 26150) were used for in vitro binding experiments. 500 uL of conditioned growth medium (with IGF-1 levels normalized to 200 ng/mL) was incubated in the wells of the tissue culture plates or with agarose beads for 1 hour at 37C. The plates or agarose beads were then washed 3 times with PBS and the bound proteins extracted with 50 ml 16 SDS loading buffer.ImmunoblottingProtein extracts from mouse tissues were prepared in RIPA lysis buffer (20 mM Tris pH 8.0, 5 mM MgCl2, 150 mM NaCl, 1 NP40, 0.1 Triton X, 1 mM NaVO4, 1 mM NaF, 1 mM PMSF, 1 ug/ml of Aprotinin and Leopeptin). 30?0 ug of protein lysates were used for 24272870 each sample, separated by SDS-page, and immunoblotted. Filters were blocked in 5 milk (Roth, T145.1) in TBST (20 mM Tris pH 7.5, 140 mM NaCl, 0.1 Tween20). Primary and secondary antibodies were diluted in.
